AAPM WGDCAB Report 372: A joint AAPM, ESTRO, ABG, and ABS report on commissioning of model-based dose calculation algorithms in brachytherapy.

The introduction of model-based dose calculation algorithms (MBDCAs) in brachytherapy provides an opportunity for a more accurate dose calculation and opens the possibility for novel, innovative treatment modalities. The joint AAPM, ESTRO, and ABG Task Group 186 (TG-186) report provided guidance to early adopters. However, the commissioning aspect of these algorithms was described only in general terms with no quantitative goals. This report, from the Working Group on Model-Based Dose Calculation Algorithms in Brachytherapy, introduced a field-tested approach to MBDCA commissioning. It is based on a set of well-characterized test cases for which reference Monte Carlo (MC) and vendor-specific MBDCA dose distributions are available in a Digital Imaging and Communications in Medicine-Radiotherapy (DICOM-RT) format to the clinical users. The key elements of the TG-186 commissioning workflow are now described in detail, and quantitative goals are provided. This approach leverages the well-known Brachytherapy Source Registry jointly managed by the AAPM and the Imaging and Radiation Oncology Core (IROC) Houston Quality Assurance Center (with associated links at ESTRO) to provide open access to test cases as well as step-by-step user guides. While the current report is limited to the two most widely commercially available MBDCAs and only for 192 Ir-based afterloading brachytherapy at this time, this report establishes a general framework that can easily be extended to other brachytherapy MBDCAs and brachytherapy sources. The AAPM, ESTRO, ABG, and ABS recommend that clinical medical physicists implement the workflow presented in this report to validate both the basic and the advanced dose calculation features of their commercial MBDCAs. Recommendations are also given to vendors to integrate advanced analysis tools into their brachytherapy treatment planning system to facilitate extensive dose comparisons. The use of the test cases for research and educational purposes is further encouraged.

A MC-based anthropomorphic test case for commissioning model-based dose calculation in interstitial breast 192-Ir HDR brachytherapy.

PURPOSE: To provide the first clinical test case for commissioning of 192 Ir brachytherapy model-based dose calculation algorithms (MBDCAs) according to the AAPM TG-186 report workflow. ACQUISITION AND VALIDATION METHODS: A computational patient phantom model was generated from a clinical multi-catheter 192 Ir HDR breast brachytherapy case. Regions of interest (ROIs) were contoured and digitized on the patient CT images and the model was written to a series of DICOM CT images using MATLAB. The model was imported into two commercial treatment planning systems (TPSs) currently incorporating an MBDCA. Identical treatment plans were prepared using a generic 192 Ir HDR source and the TG-43-based algorithm of each TPS. This was followed by dose to medium in medium calculations using the MBDCA option of each TPS. Monte Carlo (MC) simulation was performed in the model using three different codes and information parsed from the treatment plan exported in DICOM radiation therapy (RT) format. Results were found to agree within statistical uncertainty and the dataset with the lowest uncertainty was assigned as the reference MC dose distribution. DATA FORMAT AND USAGE NOTES: The dataset is available online at http://irochouston.mdanderson.org/rpc/BrachySeeds/BrachySeeds/index.html,https://doi.org/10.52519/00005. Files include the treatment plan for each TPS in DICOM RT format, reference MC dose data in RT Dose format, as well as a guide for database users and all files necessary to repeat the MC simulations. POTENTIAL APPLICATIONS: The dataset facilitates the commissioning of brachytherapy MBDCAs using TPS embedded tools and establishes a methodology for the development of future clinical test cases. It is also useful to non-MBDCA adopters for intercomparing MBDCAs and exploring their benefits and limitations, as well as to brachytherapy researchers in need of a dosimetric and/or a DICOM RT information parsing benchmark. Limitations include specificity in terms of radionuclide, source model, clinical scenario, and MBDCA version used for its preparation.

Dosimetric accuracy of the Convolution algorithm for Leksell Gamma Plan radiosurgery treatment planning: Evaluation in the presence of clinically relevant inhomogeneities.

PURPOSE: The Leksell Gamma Plan Convolution algorithm (LGP-Convolution) has not been widely adopted. This mainly stems from the higher calculated beam-on times relative to the standard ray tracing-based LGP-TMR10 dose calculation algorithm. This study aims to evaluate the accuracy of the LGP-Convolution in scenarios where the treated lesions are in the vicinity of or encompassed by bone and/or air inhomogeneities. METHODS: The solid water dosimetry phantom provided by the vendor was modified to include bone and air inhomogeneities. Two treatment planning scenarios were investigated involving a single shot and multiple shots, respectively. Treatment planning and dose prescription were performed using the LGP-Convolution algorithm. Triple channel film dosimetry was performed using GafChromic EBT3 films calibrated in terms of absorbed dose to water in a 60 Co beam. Monte Carlo (MC) simulation dosimetry was also performed in the inhomogeneous experimental geometry using the EGSnrc MC platform and a previously validated sector-based phase-space source model. MC simulations were also employed to determine correction factors required for converting EBT3 measurements at points within the bone and air inhomogeneities from dose-to-water values to the corresponding dose to medium values. RESULTS AND CONCLUSIONS: EBT3 dose to medium correction factors ranged with field size (4, 8, or 16 mm) within 0.941-0.946 for bone and 0.745-0.749 for air inhomogeneities. An excellent agreement was found between the LGP-Convolution calculations with corresponding EBT3 and MC dose to medium results at all measurement points, except those located inside the air inhomogeneity. The latter is of no clinical importance and excluding them yielded gamma index passing rates of nearly 100% for 3% local dose difference and 1 mm distance-to-agreement criteria. The excellent agreement observed between LGP-Convolution calculations and film as well as MC results of dose to medium indicates that the latter is the quantity reported by the LGP-Convolution.

Dosimetry in 1.5 T MR-Linacs: Monte Carlo determination of magnetic field correction factors and investigation of the air gap effect.

BACKGROUND: In Magnetic Resonance-Linac (MR-Linac) dosimetry formalisms, a new correction factor, kB,Q , has been introduced to account for corresponding changes to detector readings under the beam quality, Q, and the presence of magnetic field, B. PURPOSE: This study aims to develop and implement a Monte Carlo (MC)-based framework for the determination of kB,Q correction factors for a series of ionization chambers utilized for dosimetry protocols and dosimetric quality assurance checks in clinical 1.5 T MR-Linacs. Their dependencies on irradiation setup conditions are also investigated. Moreover, to evaluate the suitability of solid phantoms for dosimetry checks and end-to-end tests, changes to the detector readings due to the presence of small asymmetrical air gaps around the detector's tip are quantified. METHODS: Phase space files for three irradiation fields of the ELEKTA Unity 1.5 T/7 MV flattening-filter-free MR-Linac were provided by the manufacturer and used as source models throughout this study. Twelve ionization chambers (three farmer-type and nine small-cavity detectors, from three manufacturers) were modeled (including their dead volume) using the EGSnrc MC code package. kB,Q values were calculated for the 10 × 10 cm2 irradiation field and for four cardinal orientations of the detectors' axes with respect to the 1.5 T magnetic field. Potential dependencies of kB,Q values with respect to field size, depth, and phantom material were investigated by performing additional simulations. Changes to the detectors' readings due to the presence of small asymmetrical air gaps (0.1 up to 1 mm) around the chambers' sensitive volume in an RW3 solid phantom were quantified for three small-cavity chambers and two orientations. RESULTS: For both parallel (to the magnetic field) orientations, kB,Q values were found close to unity. The maximum correction needed was 1.1%. For each detector studied, the kB,Q values calculated for the two parallel orientations agreed within uncertainties. Larger corrections (up to 5%) were calculated when the detectors were oriented perpendicularly to the magnetic field. Results were compared with corresponding ones found in the literature, wherever available. No considerable dependence of kB,Q with respect to field size (down to 3 × 3 cm2 ), depth, or phantom material was noticed, for the detectors investigated. As compared to the perpendicular one, in the parallel to the magnetic field orientation, the air gap effect is minimized but is still considerable even for the smallest air gap considered (0.1 mm). CONCLUSION: For the 10 × 10 cm2 field, magnetic field correction factors for 12 ionization chambers and four orientations were determined. For each detector, the kB,Q value may be also applied for dosimetry procedures under different irradiation parameters provided that the orientation is taken into account. Moreover, if solid phantoms are used, even the smallest asymmetrical air gap may still bias small-cavity chamber response. This work substantially expands the availability and applicability of kB,Q correction factors that are detector- and orientation-specific, enabling more options in MR-Linac dosimetry checks, end-to-end tests, and quality assurance protocols.

Spatial distribution of the imaging dose and characterization of the scatter radiation contribution in CyberKnife radiosurgery.

PURPOSE: The imaging dose for intra- and extra-cranial CyberKnife radiosurgery applications was calculated and the scattered radiation reaching the digital detectors was quantified and analyzed with regard to its origin. METHODS: The image guidance subsystem of the CyberKnife was modeled based on vendor-provided information. The emitted X-ray energy spectrum for 120 kV was estimated using the SpekPy software tool. Monte Carlo (MC) image acquisition simulations were performed to calculate the total, primary and scattered photon fluences reaching each detector as a function of the imaged object dimensions. MC calculations of the imaging dose were performed for intra- and extra-cranial applications assuming 120 kV and 10 mAs acquisition settings. RESULTS: The amount of scattered radiation reaching each detector was found to depend on the dimensions of the imaged anatomical region, contributing more than 40 % to the total photon fluence for regions more than 20 cm thick. More than 20 % of this scattered radiation originates from the contralateral imaging field. A maximum organ dose of 1.5 mGy at the nasal bones and an average dose of 0.37 mGy to the eye lenses per image pair acquisition was calculated for head applications. An entrance imaging dose of 0.4 mGy was calculated for extracranial applications. CONCLUSIONS: Scattered radiation reaching each detector in the skull and spine tracking applications can be reduced by acquiring the pair of radiographs sequentially instead of simultaneously. A dose of 3.7 cGy to the eye lenses is estimated assuming 100 image pair exposures required for treatment completion.

GEC-ESTRO ACROP recommendations on calibration and traceability of HE HDR-PDR photon-emitting brachytherapy sources at the hospital level.

The vast majority of radiotherapy departments in Europe using brachytherapy (BT) perform temporary implants of high- or pulsed-dose rate (HDR-PDR) sources with photon energies higher than 50 keV. Such techniques are successfully applied to diverse pathologies and clinical scenarios. These recommendations are the result of Working Package 21 (WP-21) initiated within the BRAchytherapy PHYsics Quality Assurance System (BRAPHYQS) GEC-ESTRO working group with a focus on HDR-PDR source calibration. They provide guidance on the calibration of such sources, including practical aspects and issues not specifically accounted for in well-accepted societal recommendations, complementing the BRAPHYQS WP-18 Report dedicated to low energy BT photon emitting sources (seeds). The aim of this report is to provide a European-wide standard in HDR-PDR BT source calibration at the hospital level to maintain high quality patient treatments.

Impact of systematic MLC positional uncertainties on the quality of single-isocenter multi-target VMAT-SRS treatment plans.

PURPOSE: To study the impact of systematic MLC leaf positional uncertainties (stemming from mechanical inaccuracies or sub-optimal MLC modeling) on the quality of intracranial single-isocenter multi-target VMAT-SRS treatment plans. An estimation of appropriate tolerance levels is attempted. METHODS: Five patients, with three to four metastases and at least one target lying in close proximity to organs-at-risk (OARs) were included in this study. A single-isocenter multi-arc VMAT plan per patient was prepared, which served as the reference for dosimetric impact evaluation. A range of leaf offsets was introduced (±0.03 mm up to ±0.30 mm defined at the MLC plane) to both leaf banks, by varying the leaf offset MLC modeling parameter in Monaco for all the prepared plans, in order to simulate projected leaf offsets of ±0.09 mm up to ±0.94 mm at the isocenter plane, respectively. For all offsets simulated and cases studied, dose distributions were re-calculated and compared with the corresponding reference ones. An experimental dosimetric procedure using the SRS mapCHECK diode array was also performed to support the simulation study results and investigate its suitability to detect small systematic leaf positional errors. RESULTS: Projected leaf offsets of ±0.09 mm were well-tolerated with respect to both target dosimetry and OAR-sparing. A linear relationship was found between D95% percentage change and projected leaf offset (slope: 12%/mm). Impact of projected offset on target dosimetry was strongly associated with target volume. In two cases, plans that could be considered potentially clinically unacceptable (i.e., clinical dose constraint violation) were obtained even for projected offsets as small as 0.19 mm. The performed experimental dosimetry check can detect potential small systematic leaf errors. CONCLUSIONS: Plan quality indices and dose-volume metrics are very sensitive to systematic sub-millimeter leaf positional inaccuracies, projected at the isocenter plane. Acceptable and tolerance levels in systematic MLC uncertainties need to be tailored to VMAT-SRS spatial and dosimetric accuracy requirements.

On the potential of 2D ion chamber arrays for high-dose rate remote afterloading brachytherapy quality assurance.

Objective. To investigate the potential of 2D ion chamber arrays to serve as a standalone tool for the verification of source strength, positioning and dwell time, within the framework of192Ir high-dose rate brachytherapy device quality assurance (QA).Approach.A commercially available ion chamber array was used. Fitting of a 2D Lorentzian peak function to experimental data from a multiple source dwell position irradiation on a frame-by-frame basis, facilitated tracking of the source center orthogonal projection on the array plane. For source air kerma strength verification, Monte Carlo simulation was employed to obtain a chamber array- and source-specific correction factor of calibration with a 6 MV photon beam. This factor converted the signal measured by each ion chamber element to air kerma in free space. A source positioning correction was also applied to lift potential geometry mismatch between experiment and Monte Carlo simulation.Main results.Spatial and temporal accuracy of source movement was verified within 0.5 mm and 0.02 s, respectively, in compliance with the test endpoints recommended by international professional societies. The source air kerma strength was verified experimentally within method uncertainties estimated as 1.44% (k = 1). The source positioning correction method employed did not introduce bias to experimental results of irradiations where source positioning was accurate. Development of a custom jig attachable to the chamber array for accurate and reproducible experimental set up would improve testing accuracy and obviate the need for source positioning correction in air kerma strength verification.Significance.Delivery of a single irradiation plan, optimized based on results of this work, to a 2D ion chamber array can be used for concurrent testing of source position, dwell time and air kerma strength, and the procedure can be expedited through automation. Chamber arrays merit further study in treatment planning QA and real time,in vivodose verification.

The Use of Genotoxicity Endpoints as Biomarkers of Low Dose Radiation Exposure in Interventional Cardiology.

The effect of the reportedly low ionizing radiation doses, such as those very often delivered to patients in interventional cardiology, remains ambiguous. As interventional cardiac procedures may have a significant impact on total collective effective dose, there are radiation protection concerns for patients and physicians regarding potential late health effects. Given that very low doses (<100 mSv) are expected to be delivered during these procedures, the purpose of this study was to assess the potency and suitability of current genotoxicity biomarkers to detect and quantitate biological effects essential for risk estimation in interventional cardiology. Specifically, the biomarkers γ-H2AX foci, dicentric chromosomes, and micronuclei, which underpin radiation-induced DNA damage, were studied in blood lymphocytes of 25 adult patients before and after interventional cardiac procedures. Even though the mean values of all patients as a group for all three endpoints tested show increased yields relative to baseline following medical exposure, our results demonstrate that only the γ-H2AX biomarker enables detection of statistically significant differences at the individual level (p < 0.001) for almost all patients (91%). Furthermore, 24 h after exposure, residual γ-H2AX foci were still detectable in irradiated lymphocytes. Their decline was found to vary significantly among the individuals and the repair kinetics of γ-H2AX foci was found to range from 25 to 95.6% of their maximum values obtained.

Source strength determination in iridium-192 and cobalt-60 brachytherapy: A European survey on the level of agreement between clinical measurements and manufacturer certificates.

BACKGROUND AND PURPOSE: Brachytherapy treatment outcomes depend on the accuracy of the delivered dose distribution, which is proportional to the reference air-kerma rate (RAKR). Current societal recommendations require the medical physicist to compare the measured RAKR values to the manufacturer source calibration certificate. The purpose of this work was to report agreement observed in current clinical practice in the European Union. MATERIALS AND METHODS: A European survey was performed for high- and pulsed-dose-rate (HDR and PDR) high-energy sources (192Ir and 60Co), to quantify observed RAKR differences. Medical physicists at eighteen hospitals from eight European countries were contacted, providing 1,032 data points from 2001 to 2020. RESULTS: Over the survey period, 77% of the 192Ir measurements used a well chamber instead of the older Krieger phantom method. Mean differences with the manufacturer calibration certificate were 0.01% ± 1.15% for 192Ir and -0.1% ± 1.3% for 60Co. Over 95% of RAKR measurements in the clinic were within 3% of the manufacturer calibration certificate. CONCLUSIONS: This study showed that the agreement level was generally better than that reflected in prior societal recommendations positing 5%. Future recommendations on high-energy HDR and PDR source calibrations in the clinic may consider tightened agreements levels.

Management of Acute Radiodermatitis in Non-Melanoma Skin Cancer Patients Using Electrospun Nanofibrous Patches Loaded with Pinus halepensis Bark Extract.

Acute radiodermatitis is the most common side effect in non-melanoma skin cancer patients undergoing radiotherapy. Nonetheless, despite the ongoing progress of clinical trials, no effective regimen has been found yet. In this study, a non-woven patch, comprised of electrospun polymeric micro/nanofibers loaded with an aqueous extract of Pinus halepensis bark (PHBE), was fabricated and clinically tested for its efficacy to prevent radiodermatitis. The bioactivity of the PHBE patch was evaluated in comparison with a medical cream indicated for acute radiodermatitis. Twelve volunteer patients were selected and randomly assigned to two groups, applying either the PHBE patch or the reference cream daily. Evaluation of radiation-induced skin reactions was performed during the radiotherapy period and 1 month afterwards according to the Radiation Therapy Oncology Group (RTOG) grading scale, photo-documentation, patient-reported outcomes (Visual Analog Scale, questionnaire), biophysical measurements (hydration, transepidermal water loss, erythema, melanin), and image analysis. In contrast with the reference product, the PHBE patch showed significant anti-inflammatory activity and restored most skin parameters to normal levels 1 month after completion of radiation therapy. No adverse event was reported, indicating that the application of the PHBE patch can be considered as a safe medical device for prophylactic radiodermatitis treatment.

Dosimetric impact of rotational errors on the quality of VMAT-SRS for multiple brain metastases: Comparison between single- and two-isocenter treatment planning techniques.

PURPOSE: In the absence of a 6D couch and/or assuming considerable intrafractional patient motion, rotational errors could affect target coverage and OAR-sparing especially in multiple metastases VMAT-SRS cranial cases, which often involve the concurrent irradiation of off-axis targets. This work aims to study the dosimetric impact of rotational errors in such applications, under a comparative perspective between the single- and two-isocenter treatment techniques. METHODS: Ten patients (36 metastases) were included in this study. Challenging cases were only considered, with several targets lying in close proximity to OARs. Two multiarc VMAT plans per patient were prepared, involving one and two isocenters, serving as the reference plans. Different degrees of angular offsets at various orientations were introduced, simulating rotational errors. Resulting dose distributions were evaluated and compared using commonly employed dose-volume and plan quality indices. RESULTS: For single-isocenter plans and 1° rotations, plan quality indices, such as coverage, conformity index and D95% , deteriorated significantly (>5%) for distant targets from the isocenter (at> 4-6 cm). Contrarily, for two-isocenter plans, target distances to nearest isocenter were always shorter (≤4 cm), and, consequently, 1° errors were well-tolerated. In the most extreme case considered (2° around all axes) conformity index deteriorated by on-average 7.2%/cm of distance to isocenter, if one isocenter is used, and 2.6%/cm, for plans involving two isocenters. The effect is, however, strongly associated with target volume. Regarding OARs, for single-isocenter plans, significant increase (up to 63%) in Dmax and D0.02cc values was observed for any angle of rotation. Plans that could be considered clinically unacceptable were obtained even for the smallest angle considered, although rarer for the two-isocenter planning approach. CONCLUSION: Limiting the lesion-to-isocenter distance to ≤4 cm by introducing additional isocenter(s) appears to partly mitigate severe target underdosage, especially for smaller target sizes. If OAR-sparing is also a concern, more stringent rotational error tolerances apply.

Leuco crystal violet-Pluronic F-127 3D radiochromic gel dosimeter.

This work reports results related to the manufacturing and optimisation of a leuco crystal violet (LCV)-Pluronic F-127 radiochromic gel dosimeter suitable for 3D radiotherapy dosimetry. A feature of this gel is that the natural gelatine polymer, which is most often used as a matrix in 3D dosimeters, is substituted with Pluronic F-127 synthetic copolymer (poly(ethylene oxide)-block-poly(propylene oxide)-block-poly(ethylene oxide). Pluronic F-127 ensures a higher transparency than gelatine, which may be beneficial for optical computed tomography readout, and improves the thermal properties in the temperature range above ~30 °C at which the gelatine physical gel converts to a solution. The optimal composition obtained comprises 2 mM LCV, 4 mM 4-(1,1,3,3-tetramethylbutyl)phenyl-polyethylene glycol (Triton X-100), 17 mM trichloroacetic acid (TCAA) and 25% Pluronic F-127. Its main dose-response features are 4‒150 Gy linear dose range (150 Gy was the maximal dose applied to gels in this work), 0.0070 Gy-1 cm-1 dose sensitivity (derived from absorbance (600 nm) = f (dose) for 6 MeV electrons, 0.88(3) Gy s-1 and 0.0156 Gy-1 cm-1 derived from optical density (Δµ) = f (dose) for 6 MV x-rays, 0.1010 Gy s-1), low initial colour (initial absorbance = 0.0429) and a diffusion coefficient of crystal violet (CV) in LCV-Pluronic of 0.054 ± 0.023 mm2 h-1. Raman spectroscopy was used to characterize LCV-Pluronic chemical changes after irradiation. Differential scanning calorimetry (DSC) revealed that LCV-Pluronic is stable in temperatures between approximately 11 °C and 56 °C. Irradiation of LCV-Pluronic gel impacts on its first sol-gel transition temperature and the thermal effect of this process-both increased with absorbed dose, which might be related to the degradation of Pluronic. LCV-Pluronic is a promising 3D dosimeter for ionising radiation applications. Further work is needed to improve LCV-Pluronic response in the low dose region, and characterize potential effects of pH, temperature during irradiation, and radiation quality/dose rate on dose response characteristics.

A comparative assessment of inhomogeneity and finite patient dimension effects in 60Co and 192Ir high-dose-rate brachytherapy.

PURPOSE: To perform a comparative study of heterogeneities and finite patient dimension effects in 60Co and 192Ir high-dose-rate (HDR) brachytherapy. MATERIAL AND METHODS: Clinically equivalent plans were prepared for 19 cases (8 breast, 5 esophagus, 6 gynecologic) using the Ir2.A85-2 and the Co0.A86 HDR sources, with a TG-43 based treatment planning system (TPS). Phase space files were obtained for the two source designs using MCNP6, and validated through comparison to a single source dosimetry results in the literature. Dose to water, taking into account the patient specific anatomy and materials (Dw,m), was calculated for all plans using MCNP6, with input files prepared using the BrachyGuide software tool to analyze information from DICOM RT plan exports. RESULTS: A general TG-43 dose overestimation was observed, except for the lungs, with a greater magnitude for 192Ir. The distribution of percentage differences between TG-43 and Monte Carlo (MC) in dose volume histogram (DVH) indices for the planning target volume (PTV) presented small median values (about 2%) for both 60Co and 192Ir, with a greater dispersion for 192Ir. Regarding the organs at risk (OARs), median percentage differences for breast V50% were 3% (5%) for 60Co (192Ir). Differences in median skin D2cc were found comparable, with a larger dispersion for 192Ir, and the same applied to the lung D10cc and the aorta D2cc. TG-43 overestimates D2cc for the rectum and the sigmoid, with median differences from MC within 2% and a greater dispersion for 192Ir. For the bladder, the median of the difference is greater for 60Co (~2%) than for 192Ir (~0.75%), demonstrating however a greater dispersion again for 192Ir. CONCLUSIONS: The magnitude of differences observed between TG-43 based and MC dosimetry and their smaller dispersion relative to 192Ir, suggest that 60Co HDR sources are more amenable to the TG-43 assumptions in clinical treatment planning dosimetry.

On the use of a novel Ferrous Xylenol-orange gelatin dosimeter for HDR brachytherapy commissioning and quality assurance testing.

PURPOSE: To evaluate a commercially available Ferrous-Xylenol Orange-Gel (FXG) dosimeter (TrueView™) coupled with Optical-Computed Tomography (OCT) read out, for 3D dose verification in an Ir-192 superficial brachytherapy application. METHODS: Two identical polyethylene containers filled with gel from the same batch were used. One was irradiated with an 18 MeV electron field to examine the dose-response linearity and obtain a calibration curve. A flap surface applicator was attached to the other to simulate treatment of a skin lesion. The dose distribution in the experimental set up was calculated with the TG-43 and the model based dose calculation (MBCA) algorithms of a commercial treatment planning system (TPS), as well as Monte Carlo (MC) simulation using the MCNP code. Measured and calculated dose distributions were spatially registered and compared. RESULTS: Apart from a region close to the container's neck, where gel measurements exhibited an over-response relative to MC calculations (probably due to stray light perturbation), an excellent agreement was observed between measurements and simulations. More than 97% of points within the 10% isodose line (80 cGy) met the gamma index criteria established from uncertainty analysis (5%/2 mm). The corresponding passing rates for the comparison of experiment to calculations using the TG-43 and MBDCA options of the TPS were 57% and 92%, respectively. CONCLUSION: TrueView™ is suitable for the quality assurance of demanding radiotherapy applications. Experimental results of this work confirm the advantage of the studied MBDCA over TG-43, expected from the improved account of scatter radiation in the treatment geometry.

A generic TG-186 shielded applicator for commissioning model-based dose calculation algorithms for high-dose-rate 192 Ir brachytherapy.

PURPOSE: A joint working group was created by the American Association of Physicists in Medicine (AAPM), the European Society for Radiotherapy and Oncology (ESTRO), and the Australasian Brachytherapy Group (ABG) with the charge, among others, to develop a set of well-defined test case plans and perform calculations and comparisons with model-based dose calculation algorithms (MBDCAs). Its main goal is to facilitate a smooth transition from the AAPM Task Group No. 43 (TG-43) dose calculation formalism, widely being used in clinical practice for brachytherapy, to the one proposed by Task Group No. 186 (TG-186) for MBDCAs. To do so, in this work a hypothetical, generic high-dose rate (HDR) 192 Ir shielded applicator has been designed and benchmarked. METHODS: A generic HDR 192 Ir shielded applicator was designed based on three commercially available gynecological applicators as well as a virtual cubic water phantom that can be imported into any DICOM-RT compatible treatment planning system (TPS). The absorbed dose distribution around the applicator with the TG-186 192 Ir source located at one dwell position at its center was computed using two commercial TPSs incorporating MBDCAs (Oncentra® Brachy with Advanced Collapsed-cone Engine, ACE™, and BrachyVision ACUROS™) and state-of-the-art Monte Carlo (MC) codes, including ALGEBRA, BrachyDose, egs_brachy, Geant4, MCNP6, and Penelope2008. TPS-based volumetric dose distributions for the previously reported "source centered in water" and "source displaced" test cases, and the new "source centered in applicator" test case, were analyzed here using the MCNP6 dose distribution as a reference. Volumetric dose comparisons of TPS results against results for the other MC codes were also performed. Distributions of local and global dose difference ratios are reported. RESULTS: The local dose differences among MC codes are comparable to the statistical uncertainties of the reference datasets for the "source centered in water" and "source displaced" test cases and for the clinically relevant part of the unshielded volume in the "source centered in applicator" case. Larger local differences appear in the shielded volume or at large distances. Considering clinically relevant regions, global dose differences are smaller than the local ones. The most disadvantageous case for the MBDCAs is the one including the shielded applicator. In this case, ACUROS agrees with MC within [-4.2%, +4.2%] for the majority of voxels (95%) while presenting dose differences within [-0.12%, +0.12%] of the dose at a clinically relevant reference point. For ACE, 95% of the total volume presents differences with respect to MC in the range [-1.7%, +0.4%] of the dose at the reference point. CONCLUSIONS: The combination of the generic source and generic shielded applicator, together with the previously developed test cases and reference datasets (available in the Brachytherapy Source Registry), lay a solid foundation in supporting uniform commissioning procedures and direct comparisons among treatment planning systems for HDR 192 Ir brachytherapy.

Supplement 2 for the 2004 update of the AAPM Task Group No. 43 Report: Joint recommendations by the AAPM and GEC-ESTRO.

Since the publication of the 2004 update to the American Association of Physicists in Medicine (AAPM) Task Group No. 43 Report (TG-43U1) and its 2007 supplement (TG-43U1S1), several new low-energy photon-emitting brachytherapy sources have become available. Many of these sources have satisfied the AAPM prerequisites for routine clinical purposes and are posted on the Brachytherapy Source Registry managed jointly by the AAPM and the Imaging and Radiation Oncology Core Houston Quality Assurance Center (IROC Houston). Given increasingly closer interactions among physicists in North America and Europe, the AAPM and the Groupe Européen de Curiethérapie-European Society for Radiotherapy & Oncology (GEC-ESTRO) have prepared another supplement containing recommended brachytherapy dosimetry parameters for eleven low-energy photon-emitting brachytherapy sources. The current report presents consensus datasets approved by the AAPM and GEC-ESTRO. The following sources are included: 125 I sources (BEBIG model I25.S17, BEBIG model I25.S17plus, BEBIG model I25.S18, Elekta model 130.002, Oncura model 9011, and Theragenics model AgX100); 103 Pd sources (CivaTech Oncology model CS10, IBt model 1031L, IBt model 1032P, and IsoAid model IAPd-103A); and 131 Cs (IsoRay Medical model CS-1 Rev2). Observations are included on the behavior of these dosimetry parameters as a function of radionuclide. Recommendations are presented on the selection of dosimetry parameters, such as from societal reports issuing consensus datasets (e.g., TG-43U1, AAPM Report #229), the joint AAPM/IROC Houston Registry, the GEC-ESTRO website, the Carleton University website, and those included in software releases from vendors of treatment planning systems. Aspects such as timeliness, maintenance, and rigor of these resources are discussed. Links to reference data are provided for radionuclides (radiation spectra and half-lives) and dose scoring materials (compositions and mass densities). The recent literature is examined on photon energy response corrections for thermoluminescent dosimetry of low-energy photon-emitting brachytherapy sources. Depending upon the dosimetry parameters currently used by individual physicists, use of these recommended consensus datasets may result in changes to patient dose calculations. These changes must be carefully evaluated and reviewed with the radiation oncologist prior to their implementation.

Time resolved dose rate distributions in brachytherapy.

PURPOSE: To investigate the biological significance of introducing time-resolved dose rate distributions (TR-DRD) in brachytherapy. MATERIALS AND METHODS: The treatment plan of a head and neck patient treated with pulsed-dose-rate (PDR) brachytherapy was considered. The TR-DRD was calculated on the basis of a Monte Carlo generated single source dose rate matrix taking into account the dose rate per source dwell position. Biologically Effective Dose (BED) was obtained considering either the mean dose rate per pulse (analytical method) or the TR-DRD (numerical method). Corresponding Tumor Control Probabilities (TCP) were calculated and compared for various PDR schemes and repair half-times from the literature. The dose of the biologically equivalent high-dose-rate (HDR) treatment schedule was also evaluated. RESULTS: The analytical method presents an overall BED underestimation (up to 2%) relative to TR-DRD results. This is associated with an analytical-based TCP underestimation which increases with dose/pulse, pulse duration and period time and decreases with total dose. The half-time of repair seems to have the largest impact on the TCP calculations, with significant differences (up to 39.1%) corresponding to the shorter repair half-times. Regarding the equivalent HDR treatment schedule, the analytical method resulted to a HDR isoeffective dose underestimation lower than 2.2% and thus does not warrant any change in the derivation of the equivalent HDR scheme. CONCLUSION: TR-DRD data should be taken into account for PDR biological effectiveness estimations, especially for short tissue repair half-times. This does not appear however to influence dose prescription of the equivalent HDR treatment schedule for mobile tongue carcinoma.

On the experimental validation of model-based dose calculation algorithms for 192Ir HDR brachytherapy treatment planning.

There is an acknowledged need for the design and implementation of physical phantoms appropriate for the experimental validation of model-based dose calculation algorithms (MBDCA) introduced recently in 192Ir brachytherapy treatment planning systems (TPS), and this work investigates whether it can be met. A PMMA phantom was prepared to accommodate material inhomogeneities (air and Teflon), four plastic brachytherapy catheters, as well as 84 LiF TLD dosimeters (MTS-100M 1 × 1 × 1 mm3 microcubes), two radiochromic films (Gafchromic EBT3) and a plastic 3D dosimeter (PRESAGE). An irradiation plan consisting of 53 source dwell positions was prepared on phantom CT images using a commercially available TPS and taking into account the calibration dose range of each detector. Irradiation was performed using an 192Ir high dose rate (HDR) source. Dose to medium in medium, [Formula: see text], was calculated using the MBDCA option of the same TPS as well as Monte Carlo (MC) simulation with the MCNP code and a benchmarked methodology. Measured and calculated dose distributions were spatially registered and compared. The total standard (k = 1) spatial uncertainties for TLD, film and PRESAGE were: 0.71, 1.58 and 2.55 mm. Corresponding percentage total dosimetric uncertainties were: 5.4-6.4, 2.5-6.4 and 4.85, owing mainly to the absorbed dose sensitivity correction and the relative energy dependence correction (position dependent) for TLD, the film sensitivity calibration (dose dependent) and the dependencies of PRESAGE sensitivity. Results imply a LiF over-response due to a relative intrinsic energy dependence between 192Ir and megavoltage calibration energies, and a dose rate dependence of PRESAGE sensitivity at low dose rates (<1 Gy min-1). Calculations were experimentally validated within uncertainties except for MBDCA results for points in the phantom periphery and dose levels <20%. Experimental MBDCA validation is laborious, yet feasible. Further work is required for the full characterization of dosimeter response for 192Ir and the reduction of experimental uncertainties.